Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor Application

- January 25th, 2019

Acerus Pharmaceuticals (TSX:ASP) is today advising that it has received a Notice of Deficiency-Withdrawal Letter for its Gynoflor New Drug Submission. As quoted in the press release: “We are disappointed with the Health Canada decision on GynoflorTM,” said Ed Gudaitis, President and CEO of Acerus Pharmaceuticals. “GynoflorTM is currently approved in over 40 countries across Europe, Asia, … Continued

Acerus Pharmaceuticals (TSX:ASP) is today advising that it has received a Notice of Deficiency-Withdrawal Letter for its Gynoflor New Drug Submission.

As quoted in the press release:

“We are disappointed with the Health Canada decision on GynoflorTM,” said Ed Gudaitis, President and CEO of Acerus Pharmaceuticals. “GynoflorTM is currently approved in over 40 countries across Europe, Asia, the Middle East, Africa and South America and we are understandably surprised that we could not obtain approval in Canada. We will study the details of the Notice and work with Medinova AG, the manufacturer and licensor of GynoflorTM, to assess our next steps.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Leave a Reply